The VAD regimen (infusional vincristine, doxorubicin and intermittent high-dose dexamethasone) is widely considered the standard salvage chemotherapy for multiple myeloma resistant to alkylating agents and is increasingly used for induction in previously untreated patients prior to high-dose chemotherapy. We investigated the VECD protocol, a VAD-based regimen using bolus injections of vincristine 1.5 mg day 1 and epirubicin 20 mg/m 2 days 2 and 3 with 1 h infusions of cyclophosphamide 200 mg/m 2 days 1-3 and oral dexamethasone 20 mg/m 2 days 1-5 as induction and salvage treatment in multiple myeloma. Fifteen previously untreated and 25 patients with relapsed or refractory myeloma were included. Cycles were repeated every 3 weeks. In the group of previously untreated patients the response rate was 53% and the median survival has not been reached at 59 months. For relapsed and refractory patients the response rate was 44% and the median survival 13 months. In the group of patients with truly refractory disease on prior chemotherapy a response rate of 47% was achieved, which appears superior to the results observed for VAD alone. The main toxicities were leukocytopenia WHO grade IV and infections grade III/IV with both toxicities being significantly more pronounced in pretreated patients. VECD appears to be an effective regimen for induction and salvage therapy in multiple myeloma. Based on the limited number of patients treated the results are comparable to those reported for VAD, with the advantage that the infusional application of vincristine and the anthracycline is omitted.
Introduction
Conventional chemotherapy of multiple myeloma consists of melphalan and steroids or multiagent chemotherapy incorporating alkylating agents other than melphalan.
1,2 The noncross-resistant VAD regimen was initially introduced for patients relapsing after or refractory to conventional chemotherapy. 3 The VAD regimen employs infusional vincristine and doxorubicin and intermittent high-dose dexamethasone. The rationale for the 4-day infusions of the chemotherapeutic agents in an attempt to prolong exposure to cytotoxic drugs is based on the long generation time and low growth fraction of myeloma cells. 4 VAD is today widely accepted as the standard salvage treatment for relapsed or refractory myeloma. It is increasingly being used as induction treatment, especially as a preparative regimen prior to high-dose treatment.
Little is known which parts of the VAD regimen are essential for efficacy, or how the regimen could be further improved. The concept of infusional chemotherapy for mul-tiple myeloma has never been proven in clinical trials, and indeed has been questioned. 5 Preclinical data suggest that cyclophosphamide may enhance the efficacy of VAD-based chemotherapeutic regimens. 6 Furthermore, clinical data indicate that cyclophosphamide, especially in intermediate to higher dose levels, is effective in melphalan-resistant disease. 7, 8 We have therefore conducted a phase II trial evaluating the safety and efficacy of non-infusional vincristine and epirubicin in addition to cyclophosphamide and high-dose dexamethasone as induction and salvage treatment in multiple myeloma.
Patients and methods
Forty patients were treated with the VECD regimen at the Department of Internal Medicine (Cancer Research), University of Essen, between June 1991 and July 1996. Fifteen patients had previously untreated multiple myeloma, 15 had refractory and 10 relapsed disease. Patients with symptomatic myeloma entered the study irrespective of age or performance status. Patients with leukocytopenia or thrombocytopenia due to myeloma infiltration of the bone marrow were also included. Refractory disease was defined as less than 50% reduction in myeloma protein after at least 4 months of prior treatment or obvious progression during chemotherapy. Patients with a previous response were included when relapsing during treatment or within 6 months after completion of prior chemotherapy. Patients receiving at least one course of VECD were considered evaluable.
Patient characteristics are given in Table 1 . Four previously untreated patients had stage II and 11 stage III disease, according to Salmon and Durie. 9 In the relapsed and refractory group five patients had stage II and 20 patients stage III disease. All 25 patients had been treated with melphalan and steroids. Four patients had also received combinations incorporating other alkylating agents and five patients had additionally received anthracyclines (VAD in three patients). One patient had also been treated with high-dose pulsed dexamethasone. Two patients had relapsed after high-dose melphalan and autologous peripheral stem cell transplantation. Twelve patients had received one line of chemotherapy, nine had received two lines of therapy and four patients had received more than two.
The VECD regimen consisted of bolus injections of vincristine (1.5 mg, day 1) and epirubicin (20 mg/m 2 , days 2 and 3) and 1 h infusions of cyclophosphamide (200 mg/m 2 , days 1-3). Dexamethasone was given orally 20 mg/m 2 days 1-5 of each cycle. Cycles were repeated every 3 weeks provided leukocyte counts were Ͼ3000/l and platelet counts Ͼ100 000/l, except in patients with marrow suppression due to myeloma infiltration. Prophylactic treatment with H 2 antagonists or omeprazole was given during dexamethasone Response to VECD was evaluated by measurement of serum and urine myeloma protein prior to treatment and at 3-week intervals during treatment. X-ray examinations of the skeleton were performed prior to treatment and repeated as clinically indicated. ␤ 2 -microglobulin was determined prior to treatment by means of the AutoDELFIA ␤ 2 -micro kit (Wallac-ADL, Freiburg, Germany). A complete response (CR) was defined as disappearance of myeloma protein in the electrophoresis of serum or urine and less than 5% myeloma cells of normal morphology on bone marrow aspiration. 10 Negative immunofixation was not required for classification as a CR. A partial response (PR) was defined as a Ͼ50% reduction of serum myeloma protein or a Ͼ75% reduction in urinary light chain. For classification as a response the myeloma protein reduction was reproduced in consecutive measurements at least 3 weeks apart. An increase in serum or urine myeloma protein by Ͼ25%, any progressive bone lesions or hypercalcemia were classified as progressive disease. Patients neither fulfilling the criteria of a response nor progressive disease were referred to as having stable disease (SD). Hematological toxicity was evaluated through blood counts once or twice weekly between chemotherapy courses. Non-hematological toxicity was assessed by a physician after each course of VECD by obtaining the history and a physical examination of the patient. Further diagnostic procedures were performed as clinically indicated. Toxicity was graded according to WHO.
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VECD treatment was given until no further reduction in myeloma protein was observed and continued for one or two additional courses in responding patients. Patients with stable disease received two to eight courses depending on the degree of myeloma protein reduction and clinical benefit in the individual patient. In patients with progressive disease or serious adverse events not compatible with further treatment VECD was discontinued.
The 2 and Mann-Whitney U tests were used to compare groups of patients for differences in pretreatment characteristics. Progression-free survival and survival were calculated from the start of treatment according to the Kaplan-Meier method. 12 The log-rank test was used to compare survival in different groups of patients.
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Results
The response rates after VECD treatment are summarized in Table 2 . Eight out of 15 previously untreated patients responded (six PR, two CR), resulting in an overall response rate of 53.3%. Six patients achieved stable disease (40%) and one patient had disease progression under therapy. In this group of patients there was no treatment-related death. There was no statistically significant difference between the patients responding to VECD and those who did not respond with regard to sex, age, stage of disease, immunoglobulin subtype or ␤ 2 -microglobulin prior to treatment. However, in the group of responding patients the median follow-up from diagnosis to start of treatment was 1.5 months as compared to 21 months for the non-responding patients, the difference being statistically significant (P = 0.041). This finding indicates a difference in disease aggressiveness and proliferative activity between the two groups of patients.
In the group of patients with pretreated myeloma three patients showed progressive disease during treatment with VECD and one patient died of treatment-related toxicity after the first course of VECD. All four patients are summarized as treatment failures in Table 2 . Ten out of 25 patients with relapsed or refractory myeloma reached stable disease and 11 achieved a partial response. The overall response rate was 44%. Seven out of the 15 patients who did not respond to prior chemotherapy showed a response (46.7%), as did four out of the 10 relapsing patients (40%). Of the five patients previously treated with an anthracycline two achieved a partial response, the others stable disease. One of the patients with a relapse after high-dose melphalan therapy had a PR. The median number of courses given was six (range 3-10) in the group of previously untreated patients and four (range 1-9) in that of relapsed or refractory patients. In both groups the response was reached after a median of three courses, but with considerable variability (range 1-6 and 1-5 in untreated and relapsing or refractory patients, respectively).
Previously untreated patients not responding to VECD or relapsing during or after treatment with VECD were offered further treatment with conventional-dose melphalan. Patients failing VECD as salvage treatment were enrolled on experimental protocols, including high-dose melphalan and autologous stem cell transplantation in one patient and allogeneic bone marrow transplantation in two patients. For the calculation of progression-free survival and survival all three transplanted patients were censored at the time of transplantation.
The median follow-up for all 40 patients from start of VECD treatment was 44 months. For patients treated with VECD as front-line therapy, the median progression-free survival for responders was 10 months (n = 8, range 4-29). The median survival for all previously untreated patients has not been reached at 59 months (n = 15, range 6+-59+), and the probability of survival was 58% at 59 months ( Figure 1 ). The median survival for patients responding to VECD was 32 months, but for the patients not responding to VECD as firstline treatment the median has not been reached. In fact, only one of the non-responders has died. The log-rank test for survival favors the group of patients who do not respond, but this difference does not reach statistical significance (Figure 2 , P = 0.21). The reason for the superior outcome for patients with less than a partial response possibly relates to differences in disease aggressiveness as discussed below.
In the group of relapsing or refractory myeloma the median progression-free survival for responders was 6 months (n = 11, range 2-20 months). The median survival for this group was 13 months (n = 25, range 2-49+ months) and the probability of survival was 12% at 49 months (Figure 1 ). The median survival for patients responding to VECD as salvage treatment was 18 months and 9 months for non-responders, the difference in survival being statistically non-significant (P = 0.58).
The hematological toxicity of VECD treatment is summarized separately for previously untreated and pretreated
Figure 1
Survival of patients after start of VECD treatment according to prior chemotherapy. The solid line represents survival of previously untreated patients, the dashed line that of patients with prior chemotherapy. Log-rank comparison of survival P = 0.0034.
Figure 2
Survival of patients receiving VECD as front-line chemotherapy according to response to VECD. The solid line represents survival of patients without a response, the dashed line that of patients with a partial or complete response. Log-rank comparison of survival P = 0. 21. patients in Table 3 . 114 courses (57%) were fully evaluable for hematological toxicity, the main reasons for exclusion being insufficient data from the intervals between courses. Toxicities were recorded irrespective of cytopenia prior to VECD due to marrow infiltration or previous therapy. Grade IV leukocytopenia was observed during 8% (4/53) and 33% (20/61) of the chemotherapy courses in previously untreated and pretreated patients with median durations of 7.5 (range 4-11) and 9 (range 4-22) days, respectively. The incidence of grade IV leukopenia was significantly higher in pretreated patients (P Ͻ 0.001). VECD is associated with mild anemia and a low incidence of severe thrombocytopenia.
196 courses of VECD (98%) were evaluable for non-hematological toxicity with infections being the most common sideeffect. WHO grade III infections led to hospitalization in 13 courses of VECD. One life-threatening and two lethal infections (grade IV) were observed, all three occurring in pretreated patients. One patient died of pneumonia during the first course of VECD and a second patient died during the second course of VECD with leukocytopenia grade IV, fever, sudden hypotonia and suspected septic shock. No relevant microorganism was found and no autopsy was performed in either of the lethal cases. One patient refractory to prior chemotherapy with severe neutropenia developed fever, hypotonia, and acute renal failure requiring temporary hemo- Numbers represent worst toxicity during each cycle as percentage of all evaluable courses for previously untreated/pretreated patients. Anemia (P = 0.008), leukopenia (P Ͻ 0.001) and thrombocytopenia (P Ͻ 0.001) were significantly more severe in pretreated patients ( 2 test).
dialysis. No relevant microorganism was found, and renal function returned to normal after 3 months. Documented bacteremia occurred during four courses, with Escherichia coli and Staphylococcus aureus being isolated once each and Staphylococcus epidermidis being isolated twice. Candidemia due to Candida albicans occurred during two courses of VECD in one pretreated patient. Constipation requiring hospitalization for subileus occurred during two cycles of VECD. One patient developed cerebral infarction with mild sequelae after the third course of VECD. This patient simultaneously received erythropoietin, and both chemotherapy and erythropoietin were discontinued after this event. Other toxicities were mild heart failure responding to diuretics and/or digitalis during three courses and steroid-associated psychosis during one course of VECD. No case of grade III/IV peripheral neurotoxicity, grade III/IV nausea and vomiting or severe dyspepsia was observed.
Discussion
In the VECD regimen the dose intensities of vincristine and epirubicin are comparable to those of vincristine and doxorubicin in the original VAD protocol, in which chemotherapy cycles are repeated every 4 weeks. 3 In VECD dexamethasone is given days 1-5 only, thereby omitting steroid administration during days of leukopenia and reducing the risk of unrecognized infection.
In previously untreated multiple myeloma the VECD regimen results in an overall response rate of 53.3% and stable disease in 40% of patients. Using similar response criteria the reported response rates for VAD as induction therapy range from 41 to 84%. [14] [15] [16] Recent results indicate that adding cyclophosphamide to VAD-based regimens may improve remission rates in previously untreated patients. In a study adding weekly 500 mg cyclophosphamide to the VAMP regimen (C-VAMP) an overall response rate of 69% was achieved, comparable to 71% of historical controls treated with VAMP alone. 17 In the latter study a higher CR rate was observed for patients treated with C-VAMP (24%) compared to VAMP alone (8%). Using the same stringent criteria for CR we observed a CR rate of 13% with VECD in this study.
The median survival of patients treated with VECD as firstline therapy has not been reached at 59 months and the probability of survival at 59 months is 58%. In a randomized trial by Attal et al, 18 the probability of survival at 5 years was 52% for patients treated with high-dose melphalan and autologous bone marrow transplantation, survival being significantly better than that of the control group receiving multiagent chemotherapy including alkylating agents and doxorubicin. The superior survival reported here for the VECD regimen may in part be due to the low number of patients treated. It may also be due to the inclusion of a larger proportion of patients in our report with less aggressive disease. The patients who achieved stable disease after VECD as primary treatment had a significantly longer follow-up from first diagnosis to the initiation of chemotherapy because of worsening of symptoms or myeloma progression. As shown in Figure 2 , these patients tend to survive longer even though they do not respond to chemotherapy as compared to the eight patients who responded. The trend for longer survival in patients who achieved stable disease could be due to a lower proliferative activity of myeloma cells in these patients, as is indicated by the longer follow-up prior to therapy. Accordingly, a long stable plateau phase after chemotherapy has been shown to be a strong predictive factor for long-term survival in multiple myeloma. 19 The overall survival for the 8 patients in the present study who responded to VECD as their primary treatment is 32 months, similar to other VAD-based protocols. [14] [15] [16] However, the long survival for patients treated with VECD as primary treatment is not due to effective salvage with conventional melphalan or experimental protocols. Only one out of seven patients refractory to VECD and only two out of eight patients relapsing after a response to VECD responded to conventional melphalan therapy. Six out of seven refractory patients and four out of eight relapsing patients did not respond to any further therapy after VECD. Two of the eight patients relapsing after an initial response to VECD had a second response to VECD.
In relapsed and refractory disease the VECD regimen resulted in a response rate of 44%, with a median overall survival of 13 months. In larger series of VAD as salvage treatment response rates of 19-61% have been reported, with median survival ranging from 6.6 to 13 months. 3, 15, 16, [20] [21] [22] [23] [24] The response to VECD appears encouraging considering the high proportion of stage III disease and the high incidence of heavily pretreated patients in this trial. Especially the patients with refractory disease, i.e. those who have not responded to 4 months of chemotherapy preceding treatment with VECD, may have a superior response rate compared to the 26% response rate in the largest study of VAD for truly refractory myeloma reported. 24 The concept of infusional chemotherapy for higher cell kill in slowly proliferating myeloma has never been subject to clinical trials. Browman et al 25 used a modified VAD regimen with 2 h infusions of vincristine and doxorubicin days 1-4 in relapsed and refractory myeloma. The response rate was 27% and median overall survival 7.6 months. They concluded that the inferior results could be due to the shortened infusion. Using 8 h infusions of the same drugs Palva et al 26 reported a response rate of 20%. However, other studies using the original VAD protocol have produced similar results to those reported by Browman et al and in all these studies patient selection could have accounted for the observed inferior results. 22, 23 The results obtained with the non-infusional VECD regimen compare favorably with infusional VAD, but the two regimens also differ in the addition of cyclophosphamide in VECD. It is possible that the inclusion of cyclophosphamide compensates for a loss in efficacy resulting from the omission of the continuous infusion of the two other cytotoxic agents. However, the omission of the infusional application of vincristine and the anthracycline has a clear practical advantage as it is cumbersome for the patient and is associated with the high costs of pumps, the need for a central venous access and potential line problems. The need for continuous infusions in the context of VAD-based regimens with or without cyclophosphamide should be tested in a randomized trial.
In summary, VECD appears to be a safe and effective regimen for induction and salvage treatment in multiple myeloma. The omission of the 24 h infusion of vincristine and doxorubicin enhances applicability of the protocol compared to infusional VAD analogs.
